Kurma, CRT launch BliNK Therapeutics to generate monoclonal antibodies

April 16, 2017

Parent B cells carry receptors; each receptor detects a single different antigen. Once a B cell receptor recognises its 'partner' antigen, the parent B cell 'matures' to produce specific antibodies in response - generating millions of 'daughter' B cells capable of producing large quantities of the same antibody.

The new platform technology allows generation of monoclonal antibodies directly from human B cells and towards specific antigens, even when the 'parent' B cells are rare or when the antigens are hard for B cells to detect.

Alain Maiore, managing partner, Kurma, said: "We're delighted to have completed our first investment with CRT and Cancer Research UK - and excited by the enormous potential of this antibody platform which has been developed and will be implemented by an expert team of scientists."

Dr Facundo Batista, BliNK's founding scientist at Cancer Research UK's London Research Institute, said: "My group carries out research to better understand how our immune system responds to infections and cancer and I am delighted our discoveries have attracted investment of fresh resources that will allow us to continue to expand and apply our knowledge in this incredibly important field of research."

Source: Cancer Research UK